We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current INZY market cap is 292.8M. The company's latest EPS is USD -1.1521 and P/E is -4.11.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -16.91M | -19.53M | -18.37M | -16.39M | -18.07M |
Net Income | -16.37M | -18.54M | -17.4M | -15.58M | -16.64M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -20.81M | -57.04M | -56.65M | -68.68M | -75.65M |
Net Income | -19.72M | -56.42M | -56.62M | -67.06M | -71.17M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 154.02M | 139.2M | 141.8M | 150.93M | 205.7M |
Total Liabilities | 19.24M | 20.8M | 38.45M | 45.34M | 45.49M |
Total Equity | 134.78M | 118.39M | 103.35M | 105.59M | 160.21M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 47.94M | 169.36M | 123.54M | 139.2M | 200.85M |
Total Liabilities | 81.16M | 11.26M | 14.27M | 20.8M | 60.37M |
Total Equity | -33.22M | 158.1M | 109.27M | 118.39M | 140.48M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -43.36M | -57.76M | -17.77M | -33.32M | -52.19M |
Investing | -8.62M | -5.4M | 13.77M | -2.56M | -47.18M |
Financing | 72.79M | 72.79M | 20.1M | 43.74M | 113.45M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -18.81M | -35.97M | -48.15M | -57.76M | -70.68M |
Investing | -8.39M | -117.18M | 42.8M | -5.4M | -53.65M |
Financing | 22.97M | 149.81M | 609k | 72.79M | 125.97M |
Market Cap | 292.8M |
Price to Earnings Ratio | -4.11 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 8.47 |
Price to Book Ratio | 2.08 |
Dividend Yield | - |
Shares Outstanding | 61.77M |
Average Volume (1 week) | 561.49k |
Average Volume (1 Month) | 782.3k |
52 Week Change | -15.96% |
52 Week High | 7.795 |
52 Week Low | 2.689 |
Spread (Intraday) | 0.49 (9.82%) |
Company Name | Inozyme Pharma Inc |
Address |
corporation trust center 1209 orange st wilmington, delaware 19801 |
Website | https://www.inozyme.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions